Alpha Cognition Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Alpha Cognition Inc. (ACOG) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -6.70% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-31
- Alpha Cognition Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was -6.70%.
- Alpha Cognition Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | -6.70% 10-K · filed 2025-03-31 |
| 2023-12-31 | 0.00% 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |